Department of Pharmacy

Permanent URI for this collectionhttp://localhost:4000/handle/123456789/1931

Browse

Filters

20245

Settings

Author: search.filters.author.Jindal, Anil B.Subject: search.filters.subject.Mechanical Engineering

Search Results

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Recent innovations in topical delivery for management of rheumatoid arthritis: a focus on combination drug delivery
    (Elsevier, 2024-08) Jindal, Anil B.; Paul, Atish Tulshiram
    Rheumatoid arthritis (RA) is an immune-mediated disease that necessitates a thorough understanding of its intricate pathophysiological mechanism for precise and effective therapeutic targeting. The European League Against Rheumatism (EULAR) has established guidelines for RA treatment, endorsing monotherapy or combination therapy with corticosteroids and synthetic disease-modifying antirheumatic drugs (sDMARDs). This review delves into clinical trials and research outcomes related to combination drug delivery, with an emphasis on the role of natural products in combination with synthetic drugs. Given the significant adverse effects associated with systemic administration, topical delivery has emerged as an alternative avenue for effective management of RA.
  • No Thumbnail Available
    Item
    An insight into risk assessment and reformulation of drug products manufactured using benzene grade carbomer: a regulatory perspective
    (Springer, 2024-07) Jindal, Anil B.
    Cancer has been an enormous pain point for patients and regulatory bodies across the globe. In Dec. 2023, the US FDA released guidance on benzene-grade carbomer formulations, which triggered pharmaceutical manufacturers to assess risk, test finished products, and reformulate drug products with benzene-grade carbomer. The immediate implementation of the stoppage of finished products with benzene-grade carbomers has threatened pharmaceutical excipients and finished product manufacturers. The gravity of this situation prompted the US Pharmacopeia to extend the deadline for discontinuation from August 1, 2025, to August 1, 2026, allowing manufacturers ample time for reformulation and regulatory compliance. There is an immediate need to understand the guidance and to learn how manufacturers should do the risk assessment and approach reformulation. This review provides an in-depth analysis of the risk assessment and reformulation processes involved in various dosage forms utilizing benzene-grade carbomer, supported by specific case studies. This review offers insights into navigating the USFDA guidelines to ensure formulation safety and compliance, thus enabling pharmaceutical practitioners to uphold the highest standards of patient care and tackle life cycle management challenges.
  • No Thumbnail Available
    Item
    Formulation strategies to overcome amphotericin B induced toxicity
    (ACS, 2024-10) Jindal, Anil B.
    Fungal infection poses a major global threat to public health because of its wide prevalence, severe mortality rate, challenges involved in diagnosis and treatment, and the emergence of drug-resistant fungal strains. Millions of people are getting affected by fungal infection, and around 3.8 million people face death per year due to fungal infection, as per the latest report. The polyene antibiotic AmB has an extensive record of use as a therapeutic moiety against systemic fungal infection and leishmaniasis since 1960. AmB has broad-spectrum fungistatic and fungicidal activity. AmB exerts its therapeutic activity at the cellular level by binding to fungal sterol and forming hydrophilic pores, releasing essential cellular components and ions into the extracellular fluid, leading to cell death. Despite using AmB as an antifungal and antileishmanial at a broad scale, its clinical use is limited due to drug-induced nephrotoxicity resulting from binding the aggregated form of the drug to mammalian sterol. To mitigate AmB-induced toxicity and to get better anti-fungal therapeutic outcomes, researchers have developed nanoformulations, self-assembled formulations, prodrugs, cholesterol- and albumin-based AmB formulations, AmB-mAb combination therapy, and AmB cochleates. These formulations have helped to reduce toxicity to a certain extent by controlling the aggregation state of AmB, providing sustained drug release, and altering the physicochemical and pharmacokinetic parameters of AmB. Although the preclinical outcome of AmB formulations is quite satisfactory, its parallel result at the clinical level is insignificant. However, the safety and efficacy of AmB therapy can be improved at the clinical stage by continuous investigation and collaboration among researchers, clinicians, and pharmaceutical companies.
  • No Thumbnail Available
    Item
    Biopolymers for enzyme immobilization
    (Wiley, 2024-10) Jindal, Anil B.
    Enzyme immobilization has shown promising applications in different fields, including pharmaceuticals, chemistry, and medicine. Immobilized enzymes are more stable, recoverable, and robust than their free forms. Enzymes act as biocatalysts for several reactions, however, there is an important role of biopolymers, which act as supporting materials. Synthesis of new functionalized supporting materials from conventional polymers or using the novel technique for immobilization can serve the multiple demands of industries to ease the multi-step process of biocatalysis. In enzyme immobilization, numerous factors play a crucial role, such as the selection of support materials, optimization of pH, temperature, reaction time, and concentration of enzyme. Moreover, the present chapter provides a compiled summary of enzyme immobilization methods or techniques, biopolymers, and their features along with newer development as well as application in the same field.
  • No Thumbnail Available
    Item
    Investigating a novel therapeutic composition for dry eye syndrome management: In vitro and in vivo studies
    (Elsevier, 2024-12) Jindal, Anil B.
    Dry eye syndrome (DES) presents a significant challenge in ophthalmic care, necessitating innovative approaches for effective management. This research article introduces a multifaceted strategy to address DES through the development of ocular inserts utilizing advanced technologies such as hot-melt extrusion (HME) and the CaliCut post-extrusion system. The formulation includes key ingredients targeting different layers of the tear film and associated inflammation, including hydroxypropyl cellulose (HPC), polyethylene glycol (PEG), castor oil, and dexamethasone. The study incorporates a Design of Experiments (DoE) approach, integrating HME and the precise stretching and cutting technique of CaliCut for manufacturing consistency and dimensional control of the inserts. The developed insert(s) have been systematically characterized for their physicochemical properties, release profile, and in vivo efficacy. In silico molecular docking studies have also been conducted to assess the binding affinities of formulation components with ocular mucin, elucidating their binding affinities. Preliminary results demonstrate promising potential for the developed insert in managing DES, offering preservative-free treatment, sustained drug delivery, and improved patient compliance. This study highlights the integration of advanced technologies and formulation strategies in ocular drug delivery for effective DES management.